Literature DB >> 25414820

Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension.

Béatrice Bonello1, Sébastien Renard1, Julien Mancini1, Sandrine Hubert1, Gilbert Habib1, Alain Fraisse1.   

Abstract

BACKGROUND: Patients with Eisenmenger syndrome (ES) carry a better prognosis from diagnosis than patients with other causes of pulmonary hypertension (PH), but their life span has not yet been clarified. AIMS: To clarify both survival from diagnosis and life span in ES, and in closed shunt with pulmonary arterial hypertension (PAH), as compared with other causes of PH.
METHODS: Data on all adult patients with PH attending our centre over the past decade was collected. Outcome was defined as death or transplantation.
RESULTS: We studied 149 patients, including 30 (20%) patients with ES and 12 (8%) patients with closed shunt with PAH. Median age at diagnosis was lower for patients with ES and closed-shunt with PAH compared to patients with other causes of PH (P<0.001 and P=0.008 respectively). Median follow-up was 4.25 years. Survival from diagnosis was longer in ES compared to other causes of PH (logrank; P=0.02) and similar between closed-shunt with PAH and other causes of PH (logrank; P=0.3). Survival rates at 3, 6 and 9 years from diagnosis were: 73%, 50% and 47% for ES, 75%, 25% and 0% for closed-shunt with PAH, 65%, 23% and 9% for other causes of PH. Life span was similar in those three groups (logrank; P=0.2 and P=0.7, respectively).
CONCLUSIONS: Life span is similar in patients with ES, with a closed-shunt associated with PAH, and in patients with other causes of PH.

Entities:  

Keywords:  Eisenmenger syndrome (ES); Pulmonary hypertension (PH); congenital heart disease; survival

Year:  2014        PMID: 25414820      PMCID: PMC4221317          DOI: 10.3978/j.issn.2223-3652.2014.10.03

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  34 in total

Review 1.  Congenital heart disease and pulmonary hypertension.

Authors:  Maurice Beghetti
Journal:  Rev Port Cardiol       Date:  2004-02       Impact factor: 1.374

2.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Authors:  M Humbert; R J Barst; I M Robbins; R N Channick; N Galiè; A Boonstra; L J Rubin; E M Horn; A Manes; G Simonneau
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

3.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

4.  Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.

Authors:  Rosa Laura E van Loon; Marcus T R Roofthooft; Hans L Hillege; Arend D J ten Harkel; Magdalena van Osch-Gevers; Tammo Delhaas; Livia Kapusta; Jan L M Strengers; Lukas Rammeloo; Sally-Ann B Clur; Barbara J M Mulder; Rolf M F Berger
Journal:  Circulation       Date:  2011-09-26       Impact factor: 29.690

5.  Coagulation in cyanotic congenital heart disease.

Authors:  A L Wedemeyer; J R Edson; W Krivit
Journal:  Am J Dis Child       Date:  1972-11

6.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.

Authors:  William E Hopkins; Alan D Waggoner
Journal:  Am J Cardiol       Date:  2002-01-01       Impact factor: 2.778

8.  Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.

Authors:  Peter M Engelfriet; Marielle G J Duffels; Thomas Möller; Eric Boersma; Jan G P Tijssen; Erik Thaulow; Michael A Gatzoulis; Barbara J M Mulder
Journal:  Heart       Date:  2006-12-12       Impact factor: 5.994

9.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.

Authors:  Steven M Kawut; Darren B Taichman; Christine L Archer-Chicko; Harold I Palevsky; Stephen E Kimmel
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

10.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

View more
  4 in total

Review 1.  Perioperative Care of Children with Eisenmenger Syndrome Undergoing Non-cardiac Surgery.

Authors:  Bibhuti B Das
Journal:  Pediatr Cardiol       Date:  2015-05-10       Impact factor: 1.655

Review 2.  Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics.

Authors:  D B Frank; B D Hanna
Journal:  Minerva Pediatr       Date:  2015-01-21       Impact factor: 1.312

3.  Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects.

Authors:  Gerhard-Paul Diller; Marc-André Körten; Ulrike M M Bauer; Oliver Miera; Oktay Tutarel; Harald Kaemmerer; Felix Berger; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2016-02-02       Impact factor: 29.983

4.  Impact of advanced medical therapy for the outcome of an adult patient with Eisenmenger syndrome.

Authors:  Eglė Ereminienė; Marija Kinderytė; Skaidrius Miliauskas
Journal:  Respir Med Case Rep       Date:  2017-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.